trending Market Intelligence /marketintelligence/en/news-insights/trending/rE5ClWX6rPOiZRsAikmz3A2 content esgSubNav
In This List

ResMed fiscal Q1 profit climbs 16.4% YOY

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


ResMed fiscal Q1 profit climbs 16.4% YOY

ResMed Inc. said its non-GAAP net income for the first quarter ended Sept. 30 amounted to 93 cents per share, compared with the S&P Global Market Intelligence consensus normalized EPS estimate of 87 cents per share.

EPS rose 14.8% year over year from 81 cents, the San Diego-based maker of medical devices said.

Non-GAAP net income totaled $135.4 million, an increase of 16.4% from $116.3 million in the year-earlier period.

GAAP net income rose 13.6% on an annual basis to $120.1 million, or 83 cents per share, from $105.7 million, or 73 cents per share.

Revenue increased 15.8% on an annual basis to $681.1 million from $588.3 million, and research and development expenses grew 23.8% on an annual basis to $48.0 million from $38.8 million.

ResMed's products help treat and manage respiratory disorders such as chronic obstructive pulmonary disease.